 |
|
UCF Nanoparticle Offers Promise for Treating Glaucoma
June 19, 2007A unique nanoparticle made in a laboratory at the University of Central Florida is proving promising as a drug delivery device for treating glaucoma, an eye disease that can cause blindness and affects millions of people worldwide.
"The nanoparticle can safely get past the blood-brain barrier making it an effective non-toxic tool for drug delivery," said Sudipta Seal, an engineering professor with appointments in UCF's Advanced Materials Processing and Analysis Center and the Nanoscience Technology Center.
The findings will be published in an article appearing in the June 28 issue of the Journal of Physical Chemistry C.
Seal and his colleagues from North Dakota State University note in the article that while barely 1-3 percent of existing glaucoma medicines penetrate into the eye, earlier experiments with nanoparticles have shown not only high penetration rates but also little patient discomfort. The miniscule size of the nanoparticles makes them less abrasive than some of the complex polymers now used in most eye drops.
Seal and his team created a specialized cerium oxide nanoparticle and bound it with a compound that has been shown to block the activity of an enzyme (hCAII) believed to play a central role in causing glaucoma.
The disease involves abnormally high pressure of the fluid inside the eye, which, if left untreated, can result in damage to the optic nerve and vision loss. High pressure occurs, in part, because of a buildup of carbon dioxide inside the eye, and the compound blocks the enzyme that produces carbon dioxide.
Seal and a team of collaborators including Sanku Mallik, of North Dakota State University, developed the research on using nanoparticles as a delivery mechanism for the compound after supervising a student summer project at UCF. Duke University undergraduate Serge Reshetnikov spent a summer studying nanoscience on UCF's Orlando campus as part of a Research Experience for Undergraduates (REU) project funded by the National Science Foundation. Reshetnikov started looking into the possibilities of using nanoparticles as drug delivery tools. Subsequent research with his advisors led to the specific application for glaucoma.
In their paper on the research, which was also supported by the National Science Foundation, Seal and Mallik note the results are "very promising" and that their nanoparticle configuration offers seemingly limitless possibilities as a non-toxic drug delivery tool.
University of Central Florida
Seal and his colleagues from North Dakota State University note in the article that while barely 1-3 percent of existing glaucoma medicines penetrate into the eye, earlier experiments with nanoparticles have shown not only high penetration rates but also little patient discomfort. The miniscule size of the nanoparticles makes them less abrasive than some of the complex polymers now used in most eye drops.
Seal and his team created a specialized cerium oxide nanoparticle and bound it with a compound that has been shown to block the activity of an enzyme (hCAII) believed to play a central role in causing glaucoma.
The disease involves abnormally high pressure of the fluid inside the eye, which, if left untreated, can result in damage to the optic nerve and vision loss. High pressure occurs, in part, because of a buildup of carbon dioxide inside the eye, and the compound blocks the enzyme that produces carbon dioxide.
Seal and a team of collaborators including Sanku Mallik, of North Dakota State University, developed the research on using nanoparticles as a delivery mechanism for the compound after supervising a student summer project at UCF. Duke University undergraduate Serge Reshetnikov spent a summer studying nanoscience on UCF's Orlando campus as part of a Research Experience for Undergraduates (REU) project funded by the National Science Foundation. Reshetnikov started looking into the possibilities of using nanoparticles as drug delivery tools. Subsequent research with his advisors led to the specific application for glaucoma.
In their paper on the research, which was also supported by the National Science Foundation, Seal and Mallik note the results are "very promising" and that their nanoparticle configuration offers seemingly limitless possibilities as a non-toxic drug delivery tool.
University of Central Florida
Glaucoma Current Events and Glaucoma News RSS1930s drug slows tumor growth
Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease.
Cataract surgery helps AMD patients; steroid improves DME; online eye health forum
This month's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy) reports on a national study that finds cataract surgery is likely to benefit patients with age-related macular degeneration (AMD) at all stages of the disease, on a clinical trial showing that the steroid triamcinolone may be effective in advanced diabetic macular edema (DME) patients when standard treatment fails, and on the public's use of two Academy-sponsored online eye health forums.
Treating ROP in tiny preemies; better glaucoma follow-up in urban clinic
Highlights of today's Scientific Program of the 2009 American Academy of Ophthalmology (AAO) - Pan-American Association of Ophthalmology (PAAO) Joint Meeting include: John T. Flynn, MD, Columbia University School of Medicine, discussing the ever-tougher challenges Eye M.D.s face in caring for the vision of the tiniest premature babies; and a report by Bradford W. Lee, MD, Stanford University School of Medicine, on barriers to glaucoma follow-up as perceived by patients in an urban, culturally diverse clinic.
First in New York: Bionic technology aims to give sight to woman blinded beginning at age 13
A 50-year-old New York woman who was diagnosed with a progressive blinding disease at age 13 was implanted with an experimental electronic eye implant that has partially restored her vision.
Toronto researchers discover novel circulation in human eye, new glaucoma treatment target
Researchers at the University of Toronto, St. Michael's Hospital and Sunnybrook Health Sciences Centre have discovered a previously unidentified form of circulation within the human eye which may provide important new insights into glaucoma, a leading cause of blindness.
Study predicts 40 percent increase in blindness in Nigeria by 2020
By 2020, 1.4 million Nigerians over age 40 will lose their sight, and the vast majority of the causes are either preventable or treatable, according to the Nigeria National Blindness and Visual Impairment Study Group.
Unlikely genetic suspect implicated in common brain defect
A genetic search that wound its way from patients to mouse models and back to patients has uncovered an unlikely gene critically involved in a common birth defect which causes mental retardation, motor delays and sometimes autism, providing a new mechanism and potentially improving treatment for the disorder.
A drug-dispensing contact lens
Taking eye drops multiple times a day can be difficult for patients to do, and because of blinking and tearing, as little as 1 to 7 percent of the dose is actually absorbed by the eye.
Clue to normal-tension glaucoma; herpes infection and corneal transplants
The July issue of Ophthalmology, the journal of the American Academy of Ophthalmology, includes two studies that may influence clinical treatment of serious eye conditions.
Cell's split personality is a major discovery into neurological diseases
Researchers at the Université de Montreal (UdeM) and the Montreal Neurological Institute (MNI), McGill University have discovered that cells which normally support nerve cell (neuron) survival also play an active and major role in the death of neurons in the eye.
More Glaucoma Current Events and Glaucoma News Articles
 |
What Your Doctor May Not Tell You About(TM) Glaucoma: The Essential Treatments and Advances That Could Save Your Sight (What Your Doctor May Not Tell You About...) by Gregory K. Harmon (Author), Nancy Intrator (Author), Catherine Wang (Contributor), Kitty Carlisle Hart (Contributor) An insidious disease, glaucoma is often misunderstood and is the leading cause of preventable blindness. Helps to dispel the myths surrounding the disease and inform readers as to the truth about glaucoma. Divided into three accessible sections, the book takes readers through the most common methods of treatment, and explores cutting-edge research and crucial new information on the effects of nutrition, exercise, and herbal medicine on glaucoma. |
 |
Native Remedies Vizu-All Plus for Eye and Capillary Health (50ml) by Native Remedies Vizu-All Plus is a 100% safe, non-addictive natural herbal remedy formulated by our team of natural health experts. Vizu-All Plus can be used consistently to safely support visual health and encourage circulation to the eyes while promoting overall systemic and immune system health. Vizu-All Plus supports the healthy functioning of the eye, thereby helping to maintain routine visual health both day and night, as well as encouraging blood flow to the optical nerve and surrounding tissues. Vizu-All Plus can make all the difference, without compromising health and without serious side effects. Use Vizu-All Plus to promote visual health and support the eye and surrounding tissues; support strength of blood capillaries in the eye; help lessen common problems associated with night vision and... |
 |
A Patient's Guide to Glaucoma by Young H Kwon (Author), John H Fingert (Author), Emily C Greenlee (Author) The Patient's Guide to Glaucoma is a very useful educational resource. The authors have done an excellent job of covering the pertinent aspects of glaucoma from the patient's perspective. It provides more complete explanations of aspects of glaucoma care than any other presently available resource. It will be very helpful to patients who want more information about medications, laser, trabeculectomy, tube-shunt surgery, and many other subjects. John S. Cohen, MD Director, Glaucoma Service Cincinnati Eye Institute, Volunteer Clinical Professor University of Cincinnati Drs. Kwon, Greenlee and Fingert are to be congratulated for creating this outstanding educational program on glaucoma. These materials provide an excellent overview of the disease and its treatment.... |
 |
Glaucoma: Expert Consult Premium Edition - Enhanced Online Features, Print, and DVD, 2-Volume Set by Tarek M. Shaarawy MD MSc (Author), Mark B. Sherwood FRCP FRCOphth (Author), Roger A. Hitchings FRCP FRCOphth (Author), Jonathan G. Crowston MD PhD (Author) Recent dramatic advances in diagnosis, as well as medical and surgical treatment, mean that you can offer your glaucoma patients more timely and effective interventions. This brand-new clinical reference delivers the comprehensive, expert guidance you need to make optimal use of these new approaches.online, in print, and on video on DVD! Get in-depth guidance on all aspects of adult and pediatric glaucoma with one volume devoted to diagnosis and medical treatment, and another that focuses on surgical techniques. Presents world-class expertise through advice from leading specialists across six continents. Captures key diagnostic findings and operative procedures with 1,200 high-quality images and photographs-1,000 in full color-that highlight nuances of glaucoma presentation and... |
 |
Herbal Eyebright Extract - 1 oz. - Liquid by Dr. Christopher Historically it has been used for "brightening" the eyes, cataracts, heavy film, and other eye problems. For best results take internally and as an eyewash. |
 |
Becker-Shaffer's Diagnosis and Therapy of the Glaucomas (Becker-Shaffers) by Robert L. Stamper MD (Author), Marc F. Lieberman MD (Author), Michael V. Drake MD (Author) Authored by three prominent specialists in the field, this text provides comprehensive coverage of diagnostic and treatment modalities for optimal glaucoma management. Revised throughout, this new edition presents the latest guidance in clinical examination, randomized trials, medical treatment, laser therapy, and surgical procedures. Hundreds of illustrations-with many classic black and white figures from the previous editions supplemented with new color images-depict the features of glaucomas and step-by-step procedures for their management, while expanded use of highlighted boxes, lists, and summary tables make the material easy to access. Evidence-based and updated information on all aspects of the glaucomas-including physiology, genetics, interventional trials, and new surgical... |
 |
Glaucoma: A Patient's Guide to the Disease by Graham E. Trope (Author) Primary or chronic open angle glaucoma is a painless condition usually associated with high pressure in the eye. It affects approximately four per cent of all people over the age of fifty. Untreated, glaucoma is a major cause of blindness worldwide. The second edition of Glaucoma: A Patient's Guide to the Disease, published in 2001, offered essential information about glaucoma and its treatment, presented in a simple question and answer format to allow patients to participate actively in the decision-making process along the road to successful maintenance of their vision. The third edition adds to and augments the previous edition by introducing important updates on new medical and surgical treatments and information on the latest techniques used to diagnose and follow... |
 |
Mechanisms of the Glaucomas: Disease Processes and Therapeutic Modalities by Joyce Tombran-Tink (Author), Joyce Tombran-Tink (Editor), Colin J. Barnstable (Editor), M. Bruce Shields (Editor) The mechanisms of the various forms of glaucoma were unknown at the outset of the twentieth century. Late in the twentieth century, two nascent areas of research were beginning to provide glimpses of what the twenty-first century held in store for the future of glaucoma: the mechanisms of glaucomatous optic neuropathy and the molecular basis of the glaucomas. In Mechanisms of the Glaucomas: Disease Processes and Therapeutic Modalities, the authors review the most current knowledge available in the field and provide a basis in which researchers can effectively study the glaucomas. The intent of the book is not primarily to describe the clinical appearances of the glaucomas nor how to manage them. Rather, it is to provide basic scientists, who are working in the field of glaucoma, with a... |
 |
Shields' Textbook of Glaucoma (Allingham, Shields' Textbook of Glaucoma) by R. Rand Allingham (Editor), Karim F Damji (Editor), Sharon Freedman (Editor), Sayoko E Moroi (Editor), George Shafranov (Editor) This popular reference on glaucoma management now offers a more practical and clinically focused textbook for ophthalmologists and residents. Readers find new or extensively updated information on cellular and molecular biology of the eye, molecular genetics and classification of glaucomas, epidemiology and public health, screening and risk assessment, congenital and developmental glaucomas with anomalies, pseudo-exfoliation syndrome, and management of the glaucoma patient and approach to treatment. Key points and "Pearls" are summarized at the end of each chapter. "Doody's Core Titles™ 2009." |
|
Glaucoma Support - 360 Cap Bottle by Universal Naturals Supports healthy eye function and helps protect against glaucoma. |
| © 2009 BrightSurf.com |